. Author manuscript; available in PMC: 2021 Sep 1.

Published in final edited form as: Gynecol Oncol. 2020 Jul 6;158(3):702–709. doi: 10.1016/j.ygyno.2020.06.481

Table 3:

Odds ratios for macroscopic residual disease based on use of menopausal hormone therapy (MHT) use before diagnosis of ovarian cancer, among women with advanced, high-grade serous carcinoma in the Ovarian Cancer Association Consortium (OCAC).

		Residual disease	OR^a (95% CI)	p for trend

MHT use	N
None (ref)	859	574 (66%)	1.0
<5 years	239	146 (61%)	0.79 (0.58, 1.06)
5+ years	290	171 (59%)	0.71 (0.54, 0.93)	0.009

ORs are adjusted for age at diagnosis. Adjusting for OCAC site and race/ethnicity did not alter the trend for inverse association.